Clinical trial NCT00982280: Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.
Official title: An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Severe Chronic Pain Due to Osteoarthritis of the Knee Taking WHO Step III Analgesics But Showing a Lack of Tolerability.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Chronic Pain
Osteoarthritis
Keywords: Osteoarthritis
pain assessment
tapentadol
centrally acting analgesic
Lead sponsor: Grünenthal GmbH
Sponsor class: INDUSTRY
First posted: 2009-09-23
Enrollment: 82
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release (PR) in participants suffering from severe chronic pain due to osteoarthritis of the knee who are taking WHO Step III analgesics and show lack of tolerability. This is a clinical effectiveness trial designed to establish a link between anticipated clinical outcomes and the clinical practice by means of selected measures of clinical and subject-reported outcome. The trial will compare the effectiveness of previous analgesic treatment (WHO Step III) with that of tapentadol hydrochloride PR treatment during defined periods of evaluation.

Detailed description: The trial will last up to 13 weeks for each subject and includes:

* One week of observation under previous analgesic treatment.
* Twelve weeks of treatment with tapentadol hydrochloride PR.

Eligibility criteria: Inclusion Criteria:

* Participants must have signed an Informed Consent Form indicating that they understand the purpose of and procedures required for the trial and are willing to participate in it.
* Participants are men or non-pregnant, non-lactating women. Sexually active women must be postmenopausal, surgically sterile, or practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double barrier method, contraceptive patch, male partner sterilization) before entry and throughout the trial. Women of childbearing potential must have a negative pregnancy test at screening.
* Participants must be appropriately communicative to verbalize and to differentiate with regard to location and intensity of the pain.
* Participants must be at least 40 years of age.
* Participants must have a diagnosis of osteoarthritis of the knee based on the American College of Rheumatology (ACR) Classification criteria:

  * Knee pain and
  * Radiographic osteophytes or
  * Knee pain and aged 40 years or above and
  * Morning stiffness of less than 30 minutes of duration and
  * Crepitus on motion.
* Participants must have pain at the reference joint which has been present for at least 3 months.
* Participant's pain must require a strong analgesic (defined as WHO Step III) as judged by the Investigator
* Participant must be taking a WHO Step III analgesic on a daily basis for at least 2 weeks prior to the Screening Visit.
* Participant must have responded to the WHO Step III analgesic, i.e., participant must have a confirmed average pain intensity score (NRS 3) of smaller or equal to 5 points during the last 3 days prior to the Screening Visit.
* Participant must report opioid-related side effects as the reason to change their analgesic
* Participant must report a rate of satisfaction with their previous analgesic regimen not exceeding "fair" on a subject satisfaction with treatment scale (5-point VRS).

Exclusion Criteria:

* Presence of a clinically significant disease or laboratory findings that in the Investigator's opinion may affect efficacy or safety assessments.
* Presence of active systemic or local infection that may, in the opinion of the Investigator, affect the efficacy, quality of life/function or safety assessments.
* History of alcohol or drug abuse, or suspicion thereof in Investigator's judgement.
* Presence of concomitant autoimmune inflammatory conditions.
* Known history of or laboratory values reflecting severe renal impairment.
* Known history of moderately or severely impaired hepatic function.
* History of or active hepatitis B or C within the past 3 months or history of HIV infection.
* History of seizure disorder or epilepsy.
* Any of the following within 1 year: mild/moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm. Severe traumatic brain injury within 15 years (consisting of 1 or more of the following: brain contusion, intracranial hematoma, either unconsciousness or post traumatic amnesia lasting more than 24 h) or residual sequelae suggesting transient changes in consciousness.
* Pregnant or breast-feeding.
* History of allergy to, or hypersensitivity to tapentadol hydrochloride or its excipients, or contraindications related to tapentadol hydrochloride including:
* participants with acute or severe bronchial asthma or hypercapnia.
* participants who have or are suspected of having paralytic ileus.
* Employees of the Investigator or trial site, with direct involvement in this trial or other trials under the direction of the Investigator or trial site, as well as family members of employees of the Investigator.
* Participation in another trial concurrently or within 4 weeks prior to the Screening Visit.
* Known to or suspected of not being able to comply with the protocol and the use of the investigational medicinal product.
* Use of monoamine oxidase inhibitors within 14 days before the Screening Visit.
* Non-stable dosing of selective serotonin reuptake inhibitors within 30 days before the Screening Visit (the doses must remain stable during the trial).
* Osteoarthritis in a flare state.
* Use of intra-articular injections of hyaluronic acid in the reference joint within 3 months before the Screening Visit.
* Presence of conditions other than OA of the reference joint that could confound the assessment or self-evaluation of pain, e.g., anatomical deformities, significant skin conditions such as abscess or syndromes with widespread pain such as fibromyalgia. Subjects with OA at joints other than the reference joint will not be excluded as long as the reference joint is the source of main pain and disability.
* History and clinical signs at the reference joint of crystal-induced (e.g., gout, pseudo-gout), metabolic, infectious and autoimmune disease.
* Any painful procedures during the trial (e.g., major surgery including the reference joint) that may, in the opinion of the Investigator, affect the efficacy or safety assessments.
* Pending litigation due to chronic pain or disability.

Primary outcomes:
measure: Responder Rate
timeFrame: 6 weeks
Secondary outcomes:
measure: Average Pain Intensity Before the Start of Tapentadol Treatment
timeFrame: Baseline
measure: Change in Average Pain Intensity After 6 Weeks of Tapentadol PR Treatment.
timeFrame: Baseline; Week 6 (6 weeks)
measure: Change in Average Pain Intensity After 12 Weeks of Tapentadol PR Treatment.
timeFrame: Baseline; Week 12 (12 weeks)
measure: Baseline Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee
timeFrame: Baseline
measure: Change From Baseline in the Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week at Week 6
timeFrame: 6 weeks
measure: Change From Baseline in the Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week at Week 12
timeFrame: 12 weeks
measure: EuroQol-5 (EQ-5D) Health Status Index Outcome Over Time
timeFrame: 6 weeks
measure: EuroQol-5 (EQ-5D) Health Status Index Outcome Over Time
timeFrame: 12 weeks
measure: Change in Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS)
timeFrame: 6 Weeks
measure: Change in Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS)
timeFrame: 12 Weeks
measure: Clinical Global Impression of Change
timeFrame: Baseline; End of Week 6 (6 Weeks)
measure: Clinical Global Impression of Change
timeFrame: Baseline; End of Week 12 (12 Weeks)
measure: Patient Global Impression of Change
timeFrame: Baseline; End of Week 6 (6 Weeks)
measure: Patient Global Impression of Change
timeFrame: Baseline; End of Week 12 (12 Weeks)
measure: Participant's Satisfaction With Previous Analgesic Treatment.
timeFrame: Baseline
measure: Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol.
timeFrame: After 6 weeks
measure: Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol.
timeFrame: After 12 weeks
measure: Mean Equipotency Ratio of Tapentadol Compared to Buprenorphine
timeFrame: Baseline; End of Week 6 (6 Weeks)
measure: Mean Equipotency Ratio of Tapentadol Compared to Oxycodone
timeFrame: Baseline; End of Week 6 (6 Weeks)
Other outcomes:
Locations:
city: Melbourne
country: Australia
facility: Site 4
city: Perth
country: Australia
facility: Site 2
city: Aalborg
country: Denmark
facility: Site 4
city: Hvidovre
country: Denmark
facility: Site 7
city: Kolding
country: Denmark
facility: Site 6
city: Odense
country: Denmark
facility: Site 2
city: Vejle
country: Denmark
facility: Site 3
city: Berlin
country: Germany
facility: Site 1
city: Katzhütte
country: Germany
facility: Site 7
city: Leer
country: Germany
facility: Site 2
city: Leipzig
country: Germany
facility: Site 8
city: Zerbst
country: Germany
facility: Site 9
city: Lublin
country: Poland
facility: Site 4
city: Ostrow Mazowiecka
country: Poland
facility: Site 5
city: Tychy
country: Poland
facility: Site 2
city: Madrid
country: Spain
facility: Site 4
city: Valencia
country: Spain
facility: Site 1
city: Birmingham
country: United Kingdom
facility: Site 3
city: Carmarthen
country: United Kingdom
facility: Site 6
city: Leeds
country: United Kingdom
facility: Site 1
city: London
country: United Kingdom
facility: Site 2
city: Middlesborough
country: United Kingdom
facility: Site 8
city: Oxford
country: United Kingdom
facility: Site 9
city: York
country: United Kingdom
facility: Site 10
Study officials:
affiliation: FRCA, FRCAPM Heart of England NHS Trust
name: Barbara Hoggart, Dr. MD
role: PRINCIPAL_INVESTIGATOR
References: